IRVINE, Calif., July 28, 2015 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today reported net income for the quarter ended June 30, 2015 of $112.7 million, or $1.02 per diluted share. Adjusted net income on a non-GAAP basis was $124.4 million, or $1.13 per diluted share, compared to $0.88 per diluted share in the prior year period. In the year ago period, GAAP net income was $5.09 per diluted share, which included a $750 million payment to Edwards from a litigation settlement.
Help employers find you! Check out all the jobs and post your resume.
